India's Plan to Restrict Quit-Aids Sparks Public Health Firestorm

NEW DELHI, India – April 17, 2026 – A controversial proposal by Indian regulators to restrict over-the-counter access to most nicotine replacement therapies (NRTs) has ignited a fierce debate, pitting public health advocates against a government body aiming for tighter control. Critics warn the move could prove disastrous for the millions of Indian smokers seeking to quit, creating a dangerous paradox where deadly cigarettes remain far easier to purchase than the tools designed to stop using them.

The sharpest criticism has come from the Coalition of Asia Pacific Tobacco Harm Reduction Advocates (CAPHRA), which has lambasted the potential policy shift. “This is public health madness,” declared CAPHRA Executive Coordinator Nancy Loucas in a statement. “If cigarettes are readily available, nicotine replacement therapies should not be harder to get.”

At the heart of the issue is a recommendation from India’s Drug Technical Advisory Board (DTAB). The board has proposed amending national drug rules to make most NRT products, including nicotine lozenges and flavored gums, available by prescription only. The only likely exception would be unflavored 2 mg nicotine gum. This move is reportedly based on a report from the Indian Council of Medical Research (ICMR) that cited concerns about the “abuse potential” of NRTs among non-smokers and the need for medical supervision.

A Policy at Odds with Itself

Public health experts argue the proposal creates a baffling inconsistency in public health policy. While NRTs would be placed behind a doctor’s prescription, combustible tobacco products—which are responsible for over 1.35 million deaths in India annually—continue to be sold with minimal barriers at countless shops across the country.

“Every extra barrier means another smoker may give up on quitting before they even start,” said Clarisse Virgino, CAPHRA’s Philippines spokesperson. “That is especially damaging for lower-income and rural communities, where access to doctors, cessation clinics and specialist support is already limited.”

This sentiment is echoed by many within India's medical community. A senior pulmonologist from a leading Delhi hospital, speaking on condition of anonymity, called the proposal a “monumental step backward.” He argued, “We have decades of real-world evidence from Western countries showing that over-the-counter NRT is safe and does not lead to widespread misuse. To ignore this evidence and restrict a WHO-approved cessation aid is to condemn more people to die from smoking-related illnesses.”

Further complicating the regulatory logic, nicotine gum was added to India’s National List of Essential Medicines in 2022. This inclusion was intended to underscore its importance and improve its accessibility within the public health system. The DTAB's new recommendation seems to directly contradict the spirit of that decision, effectively making an “essential medicine” harder for patients to obtain.

The Global Consensus on Quitting

India’s proposed restrictions stand in stark contrast to global public health consensus and international practice. The World Health Organization (WHO) actively promotes NRTs as a cornerstone of tobacco cessation efforts and encourages countries to improve their availability, particularly in low- and middle-income nations. In fact, the WHO recently prequalified a nicotine gum and patch to help increase global access to these vital medications.

Scientific evidence overwhelmingly supports the safety and efficacy of NRTs. A landmark 2019 Cochrane Review, a gold standard in evidence-based medicine, found that NRTs can increase a smoker’s chance of successfully quitting by 50 to 70 percent. The review also highlighted that combining a slow-acting form, like a patch, with a fast-acting one, like a gum or lozenge, is even more effective than using a single product. These are precisely the products that would become harder to access under the new proposal.

“These products are not magic bullets, and they are not risk-free,” Loucas acknowledged. “But they are established quit aids, and good policy should make them easier to access, not harder.”

More than 100 countries, including the United States and the United Kingdom, have permitted over-the-counter sales of NRTs for years, viewing wider accessibility as a critical component of their tobacco control strategies.

India's Crossroads: Control vs. Harm Reduction

The debate over NRTs exposes a deep fault line in India's approach to tobacco control. On one side are regulators who favor a strict, abstinence-only approach, viewing all nicotine products with suspicion. This perspective led to India's complete ban on e-cigarettes and heated tobacco products in 2019. On the other side are harm reduction proponents who argue that providing safer alternatives is a pragmatic and life-saving strategy for adult smokers who cannot or will not quit.

A letter published in the peer-reviewed Indian Journal of Psychiatry had already warned that existing regulations were hampering access to treatment for tobacco dependence, arguing that such restrictions run counter to public health goals.

The potential public health fallout is immense. With a significant portion of Indian tobacco users expressing a desire to quit, making the first step harder could deter countless quit attempts before they even begin. The burden would fall heaviest on those with the fewest resources, exacerbating health inequalities.

As Indian regulators weigh their final decision, they face a critical choice that could have a profound impact on the future of tobacco control not only within India but across the Asia Pacific region. The outcome will determine whether policy prioritizes strict control over all nicotine or embraces evidence-based tools that offer millions a pathway away from the nation's deadliest consumer product.